[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ii-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ii-lung-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100460869","avecure-flexible-microwave-ablation-probe-for-lung-nodules-100460869",false,"NCT05281237","Avecure Flexible Microwave Ablation Probe For Lung Nodules","Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule","Inclusion Criteria:\n\n* Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.\n* Pathological proof of target nodule\u002Ftumor type and malignancy with specimen considered adequate per institutional laboratory standards\n* Target nodule\u002Ftumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively\n* Resection\u002Fsurgical candidate (lobectomy or greater)\n* Participants must be at least 22 years old and able to provide consent\n\nExclusion Criteria:\n\n* Subjects in whom flexible bronchoscopy is contraindicated\n* Target nodule \\\u003C 1.0 cm\n* Prior radiation or neo adjuvant chemotherapy of the target nodule\u002Ftumor\n* Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives\n* Pacemaker, implantable cardioverter, or another electronic implantable device\n* Patient cannot tolerate bronchoscopy\n* Patients with coagulopathy\n* Patients in other therapeutic lung cancer studies\n* Subject is pregnant or breastfeeding\n* COVID-19 positive patient at the time of procedure.","ALL","22 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.\n\nThis research study involves microwave ablation (MWA)",[26,27,28,29,30,31],"Stage I - II Primary Lung Cancer","Stage I Lung Cancer","Stage II Lung Cancer","Lung Cancer Stage I","Lung Cancer Stage II","Lung Cancer",[33,27,28,29,30,31],"Stage I - II primary lung cancer","RECRUITING","2026-04-07",{"date":37,"type":38},"2026-04-08","ACTUAL",{"date":40,"type":38},"2022-06-01",{"date":42,"type":20},"2027-06-30",{"name":44,"class":45},"Beth Israel Deaconess Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100624623","precise-exercise-regimen-for-cancer-care-percc-a-pilot-study-100624623","NCT07412041","Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study","PERCC","Inclusion Criteria:\n\n* Age ≥18 years at time of diagnosis; due to the rarity of the disease in those \\\u003C18 years, this age bracket will not be included.\n* Histologically diagnosed with stage II or III non-small cell lung cancer (NSCLC) and has not started lung cancer treatment.\n* Patient's treatment plan is to receive neoadjuvant therapy (defined as chemotherapy, chemotherapy and immunotherapy, or chemotherapy and radiation therapy) followed by surgical treatment. Patients will be enrolled at least three weeks prior to receiving their first neoadjuvant treatment.\n* Ability to follow directions and complete questionnaires in English and\u002For Spanish.\n* Ability to understand and the willingness to sign a written informed consent document prior to any study-related procedures.\n* Willing to travel to DFCI for necessary data collection.\n\nExclusion Criteria:\n\n* Patients who are morbidly obese (BMI\\>40 kg\u002Fm2) or Anorexic (BMI\\\u003C17 kg\u002Fm2).\n* Unstable comorbidities that contraindicate participation in exercise program compliance. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded. Study staff will identify untreated or unmanaged conditions when screening and treating MDs must provide clearance prior to patient enrollment.\n* Patients with alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer).\n* Patients scheduled to receive single modality cancer treatment (unimodal therapy), scheduled surgery within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started.\n* Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.\n* Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.","18 Years",{"count":56,"type":20},20,[23],"The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.",[28,31,60,61],"Non-small Cell Lung Cancer","NSCLC",[28,31,60,61],"NOT_YET_RECRUITING","2026-02-09",{"date":66,"type":38},"2026-02-17",{"date":68,"type":20},"2026-07",{"date":70,"type":20},"2028-09-30",{"name":72,"class":45},"Dana-Farber Cancer Institute",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":46},"100561664","cryodevitalization-for-the-treatment-of-early-stage-lung-cancer-crystal-trial-100561664","NCT06593106","Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial","The CRYSTAL Study: Cryodevitalization Study for the Treatment of Early-Stage Lung Cancer","Inclusion Criteria:\n\n* Patients with a single pulmonary nodule with a size less than or equal to three centimeters (average long and short axis) confirmed as malignant intraprocedurally (rapid on-site evaluation with pathology assessment showing lung cancer or oligometastatic disease) without evidence of mediastinal involvement who require nodule biopsy prior to proceeding with surgical resection\n* Nodules must be located in the outer 2\u002F3 of the periphery of the lung, greater than 10 mm from the pleura and from large blood vessels or mediastinal structures to avoid injury to other visceral organs\n* Patients deemed to have a surgical resection treatment option based on preoperative staging computed tomographic (CT), postoperative predicted forced expiratory volume in 1 second (FEV1) \\> 40% and evaluation of medical comorbidities after discussion at multidisciplinary tumor board\n* Age \\> 18 years old\n\nExclusion Criteria:\n\n* Target nodule is within the International Association for the Study of Lung Cancer (IASLC) \"central zone\" (including bronchial tree, major vessels, heart, esophagus, spinal cord and phrenic \\& laryngeal nerves), or are \\\u003C 10 mm from the pleura\n* Patients with an expected survival less than 6 months\n* Patients with endobronchial lesions, concerning for malignancy, visualized during the initial bronchoscopic evaluation of the airways\n* Patients with medically uncorrectable coagulopathy: abnormal platelet count \\\u003C 100 × 10\\^9\u002FL or an international normalized ratio \\> 1.5\n* Patients with known pulmonary hypertension (PASP \\[pulmonary artery systolic pressure\\] \\> 50mmHg)\n* Patients who are currently prescribed anticoagulants, clopidogrel, or other platelet aggregation inhibitors\n* Patients with medical comorbidities deemed high-risk for surgical resection\n* Pregnant women\n* Inability to provide informed consent",{"count":81,"type":20},30,[23],"This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at the time of standard diagnostic robotic bronchoscopy. Using cryodevitalization may be safe, tolerable and\u002For effective in treating patients with early stage lung cancer.",[27,28],"2026-01-29",{"date":87,"type":38},"2026-02-02",{"date":89,"type":38},"2024-09-27",{"date":91,"type":20},"2026-08-31",{"name":93,"class":45},"Vanderbilt-Ingram Cancer Center"]